Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pravastatin
Drug ID BADD_D01824
Description Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Indications and Usage For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
Marketing Status Prescription; Discontinued
ATC Code C10AA03
DrugBank ID DB00175
KEGG ID D08410
MeSH ID D017035
PubChem ID 54687
TTD Drug ID D02RQU
NDC Product Code Not Available
Synonyms Pravastatin | Eptastatin | Vasten | CS-514 | CS 514 | CS514 | Lin-Pravastatin | Lin Pravastatin | Lipemol | Liplat | Nu-Pravastatin | Nu Pravastatin | Prareduct | Mevalotin | Pravachol | Elisor | Selektine | Lipostat | Pravacol | Pravasin | Pravastatin Monosodium Salt, (6 beta)-Isomer | Pravastatin Sodium | Pravastatin Sodium Salt | Sodium Salt, Pravastatin | Pravastatin tert-Octylamine Salt | Pravastatin tert Octylamine Salt | Pravastatin, (6 beta)-Isomer | RMS-431 | RMS 431 | RMS431 | SQ-31000 | SQ 31000 | SQ31000 | SQ-31,000 | SQ 31,000 | SQ31,000 | Apo-Pravastatin | Apo Pravastatin | Bristacol
Chemical Information
Molecular Formula C23H36O7
CAS Registry Number 81093-37-0
SMILES CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute myocardial infarctionStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Angina pectorisStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
AngioplastyStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
ArteriosclerosisLiver carboxylesterase 1P23141T763699420339; 14660992; 14998629; 14984434
Cerebrovascular accidentStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
DeathStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Myocardial ischaemiaApolipoprotein EP02649T2168910736278; 7605354
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral nerve palsy17.01.04.017--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Antinuclear antibody positive13.06.01.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.01.01.003--Not Available
Lung infection22.07.01.008; 11.01.09.008--
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Drug intolerance08.06.01.0130.000145%Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Muscle swelling15.05.03.015--Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.0030.000109%Not Available
Acute kidney injury20.01.03.0160.000047%
Immune-mediated necrotising myopathy10.04.05.006; 15.05.05.008--Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.010--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.000072%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000028%
Liver function test increased13.03.01.0440.000072%Not Available
Cerebellar haematoma24.07.04.022; 17.08.01.0450.000072%Not Available
The 7th Page    First    Pre   7    Total 7 Pages